T
TMS Co Ltd
TSE:4891
TMS Co Ltd
TSE:4891
Price:
243 JPY
1.67%
Market Closed
Updated:
May 15, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of TMS Co Ltd.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
Not Available
T
Valuation Multiples
Multiples Across Competitors
Competitors Multiples
TMS Co Ltd Competitors
TMS Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| JP |
T
|
TMS Co Ltd
TSE:4891
|
8.9B JPY | 0 | -13.2 | -8.7 | -8.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
285.4B USD | 5.3 | 59.2 | 12.9 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
167B USD | 5.7 | 44.4 | 18.7 | 30.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.4B USD | 11.2 | 30.5 | 24.6 | 25.8 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108.5B USD | 8.3 | 28.1 | 22.8 | 25.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36.2 | 21.9 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
84.3B USD | 3.1 | 174.2 | 7 | 9.2 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
49.1B USD | 9.5 | -8.2 | -9 | -8 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33B USD | 3.4 | 28.3 | 14.4 | 18 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.6T KRW | 18.2 | 73.8 | 45.2 | 62.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
